FRUQUINTINIB

Brand name:

• Fruzaqla®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Metastatic colorectal cancer (mCRC)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (–)

Comment:

To be considered at a future PBAC meeting

Submission sponsor:

TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.

Other PBAC consideration:

--

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Not applicable

PBAC outcome published:

Not Applicable (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---